BMS-986120 MAD and Midazolam Interaction Study

Phase 1, randomised, double-blind trial of BMS-986120 in arterial thrombosis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of subjects experiencing serious adverse events, deaths, adverse events leading to discontinuation, and potential clinically significant changes in ECG parameters up to 168 days and Percent of subjects experiencing serious adverse events, deaths, adverse events leading to discontinuation, and potential clinically significant changes in ECG parameters up to 168 days. Started Aug 2014; status: completed.